Latest Revenue Growth News

Activeport Group Ltd reported a strong Q4 FY25 with significant revenue growth in software and Network as a Service segments, underpinned by new contracts with leading telecom providers and improved cash flow management.

Energy Technologies Limited reported a modest revenue increase and significant cash outflow improvement in its latest quarterly update, while preparing strategic moves to manage liquidity.

Medical Developments International (MVP) reports positive operating cash flow in H2 FY25, driven by strong Penthrox sales and strategic distribution shifts in Europe. The company eyes further growth amid regulatory progress and efficiency gains.

IODM Limited reported a robust 37% increase in cash receipts for Q4 FY25, driven by strong UK education sector growth and new international revenue share agreements.

Resonance Health reports a solid quarter with key clinical trial milestones, expansion of trial sites, and multi-year Software-as-a-Medical Device contracts, underpinning a positive cashflow outlook.

Starpharma reports a 165% rise in FY25 customer receipts, advances its clinical-stage DEP® assets, and secures new distribution deals in Asia and Saudi Arabia.

Hydrix Limited reports steady June quarter revenues with a 10% rise from the prior quarter, supported by new contract wins and a robust $40 million project pipeline.

Airtasker Limited has reported its second consecutive year of positive free cash flow alongside robust revenue growth, fueling accelerated expansion in the UK and US marketplaces.

Mad Paws Holding Limited reported modest revenue growth and improved cash flow in Q4 2025, while progressing a significant acquisition deal with Rover Group and divesting its Pet Chemist business.

MedAdvisor Solutions reported a 16.6% revenue decline in 4Q FY25, driven by US market challenges, while completing the sale of its ANZ business and initiating a strategic review of its US operations.

Airtasker Limited reports its second consecutive year of positive free cash flow alongside a 29% jump in marketplaces revenue, driven by explosive growth in the UK and US markets.

MedAdvisor reports a significant revenue decline in FY25 amid US program delays but strengthens its balance sheet through a capital raise and ANZ business sale. The company signals a strategic pivot with potential US business divestment on the horizon.